The Effect of Fluticasone Nasal Spray on Patients with Chronic Rhinitis and Chronic Obstructive Pulmonary Disease

<b>Background:</b> Although upper and lower respiratory tract diseases coexist, studies discussing the relationship between chronic rhinitis (CR) and chronic obstructive pulmonary disease (COPD) are limited. Fluticasone nasal sprays are common treatment options for patients with rhinitis. Therefore, we aimed to investigate the effects of fluticasone nasal spray on patients with both CR and COPD. <b>Methods</b>: A retrospective review was performed using data from former smokers with CR and COPD at China Medical University Hospital (CMUH). Based on their medication history, patients were allocated into Group A, who had received treatment with fluticasone nasal spray, and Group B, who had never received this treatment. Pulmonary function test results, including forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC), were collected for both groups before treatment and one year after treatment. Statistical analysis was performed to evaluate the impact of fluticasone nasal spray treatment on pulmonary function. <b>Results</b>: A total of 123 former smokers were included, with 62 patients in Group A and 61 patients in Group B. At baseline, there was no significant difference in age, sex, and pulmonary function between the two groups. After one year of treatment, Group A showed an upward trend in pulmonary function, with the FEV1 increasing from 1.613 ± 0.554 to 1.708 ± 0.675 (<i>p</i> < 0.05) and the FVC increasing from 2.540 ± 0.694 to 2.670 ± 0.839 (<i>p</i> < 0.05). On the other hand, Group B exhibited a downward trend in pulmonary function after one year, with the FEV1 decreasing from 1.609 ± 0.554 to 1.544 ± 0.517 (<i>p</i> < 0.05) and the FVC decreasing from 2.586 ± 0.665 to 2.495 ± 0.679 (<i>p</i> < 0.05). <b>Conclusions</b>: This retrospective study suggests that the combined use of fluticasone nasal spray may be associated with improved pulmonary function in former smokers with both CR and COPD. This finding supports the concept of "united airway disease".

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2025-05-22
DOI
https://doi.org/10.3390/jcm14113637
Citations
1
Primary Topic
Asthma and respiratory diseases
Type
article
Field-Weighted Citation Impact
1.16

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Effect of Fluticasone Nasal Spray on Patients with Chronic Rhinitis and Chronic Obstructive Pulmonary Disease

Zhengyan Dai, Yung‐An Tsou, Chih‐Jaan Tai, Chien‐Lin Liu et al.
1 citations
Journal of Clinical Medicine
Asthma and respiratory diseases
1.16
article

The Effect of Fluticasone Nasal Spray on Patients with Chronic Rhinitis and Chronic Obstructive Pulmonary Disease

Zhengyan Dai, Yung‐An Tsou, Chih‐Jaan Tai, Chien‐Lin Liu, Liang‐Chun Shih, Yuting Li, Jin-Yi Lin, Chia‐Der Lin
article en
1 citations

Abstract

<b>Background:</b> Although upper and lower respiratory tract diseases coexist, studies discussing the relationship between chronic rhinitis (CR) and chronic obstructive pulmonary disease (COPD) are limited. Fluticasone nasal sprays are common treatment options for patients with rhinitis. Therefore, we aimed to investigate the effects of fluticasone nasal spray on patients with both CR and COPD. <b>Methods</b>: A retrospective review was performed using data from former smokers with CR and COPD at China Medical University Hospital (CMUH). Based on their medication history, patients were allocated into Group A, who had received treatment with fluticasone nasal spray, and Group B, who had never received this treatment. Pulmonary function test results, including forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC), were collected for both groups before treatment and one year after treatment. Statistical analysis was performed to evaluate the impact of fluticasone nasal spray treatment on pulmonary function. <b>Results</b>: A total of 123 former smokers were included, with 62 patients in Group A and 61 patients in Group B. At baseline, there was no significant difference in age, sex, and pulmonary function between the two groups. After one year of treatment, Group A showed an upward trend in pulmonary function, with the FEV1 increasing from 1.613 ± 0.554 to 1.708 ± 0.675 (<i>p</i> < 0.05) and the FVC increasing from 2.540 ± 0.694 to 2.670 ± 0.839 (<i>p</i> < 0.05). On the other hand, Group B exhibited a downward trend in pulmonary function after one year, with the FEV1 decreasing from 1.609 ± 0.554 to 1.544 ± 0.517 (<i>p</i> < 0.05) and the FVC decreasing from 2.586 ± 0.665 to 2.495 ± 0.679 (<i>p</i> < 0.05). <b>Conclusions</b>: This retrospective study suggests that the combined use of fluticasone nasal spray may be associated with improved pulmonary function in former smokers with both CR and COPD. This finding supports the concept of "united airway disease".

Journal of Clinical MedicineVol. 14(11)
Asia University (TW), China Medical University (TW), China Medical University Hospital (TW)
China Medical University Hospital
Good health and well-being
Openalex Percentile: Top 22%
Asthma and respiratory diseases
1.16
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.